Detalhe da pesquisa
1.
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.
Eur Heart J
; 2023 Mar 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36879424
2.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Circulation
; 146(9): 657-672, 2022 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35770629
3.
Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study.
Arterioscler Thromb Vasc Biol
; 42(12): 1447-1457, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36325897
4.
Effect of alirocumab on cataracts in patients with acute coronary syndromes.
BMC Ophthalmol
; 23(1): 279, 2023 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37328736
5.
First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protection.
Br J Clin Pharmacol
; 87(2): 598-611, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32520410
6.
Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes.
BMC Ophthalmol
; 23(1): 301, 2023 Jul 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37415129
7.
Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
JAMA Pediatr
; 178(3): 283-293, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38315470
8.
Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome.
Can J Cardiol
; 39(10): 1315-1324, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37116789
9.
Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis.
Crit Care Explor
; 5(11): e0997, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37954898
10.
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Lancet Diabetes Endocrinol
; 10(5): 330-340, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35378068
11.
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
J Am Coll Cardiol
; 78(5): 421-433, 2021 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34325831
12.
PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study.
J Clin Lipidol
; 14(3): 322-330.e5, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32331936
13.
Corrigendum to PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study Volume 14, Issue 3, May-June 2020, Pages 322-330.e5.
J Clin Lipidol
; 14(5): 741, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33138961
14.
Lot-to-lot consistency of a combined hexavalent diptheria-tetanus-acellular-pertussis, hepatitis B, Inactivated polio and haemophilus B conjugate vaccine, administered to healthy chilean infants at two, four and six months of age.
Hum Vaccin
; 1(3): 112-7, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-17012870